Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies
Hao Huang(Zhengzhou University), Zibing Wang(Huazhong University of Science and Technology), Bicheng Zhang(University of Electronic Science and Technology of China), Quanli Gao(Zhengzhou University), Brian G. Till(University of Washington), Xiang Yan(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Tiepeng Li(East China Normal University), Hongle Li(Shanghai Jiao Tong University), Xiaomin Fu(Zhengzhou University), Zhenlong Ye(Shanghai University), Lingdi Zhao(Zhengzhou University), Ling Peng(Guangzhou University of Chinese Medicine), Yonghao Yang(Army Medical University), Yang Liu(Shanxi Medical University), Lin Chen(Shanghai Jiao Tong University), Xiaojie Zhang(Shanghai University of Traditional Chinese Medicine), Lu Han(Liaoning Cancer Hospital & Institute), Peng Qin(Shenzhen Bay Laboratory), Wenkang Wang(ZheJiang Institute For Food and Drug Control)
Cited by 6
Related Papers
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
|Journal of Allergy and Clinical Immunology|2020|694
Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections
|medRxiv|2020|692
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594